4.44
+0.02(+0.45%)
Currency In USD
| Previous Close | 4.42 |
| Open | 4.34 |
| Day High | 4.49 |
| Day Low | 4.33 |
| 52-Week High | 9.33 |
| 52-Week Low | 2.95 |
| Volume | 172,520 |
| Average Volume | 172,544 |
| Market Cap | 251.08M |
| PE | -3.89 |
| EPS | -1.14 |
| Moving Average 50 Days | 4.62 |
| Moving Average 200 Days | 4.65 |
| Change | 0.02 |
If you invested $1000 in Foghorn Therapeutics Inc. (FHTX) since IPO date, it would be worth $245.03 as of November 12, 2025 at a share price of $4.44. Whereas If you bought $1000 worth of Foghorn Therapeutics Inc. (FHTX) shares 3 years ago, it would be worth $516.88 as of November 12, 2025 at a share price of $4.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
GlobeNewswire Inc.
Oct 30, 2025 11:30 AM GMT
- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors - Selective CBP degrader is on track for non-GLP to
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
GlobeNewswire Inc.
Oct 16, 2025 11:00 AM GMT
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDTCAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
GlobeNewswire Inc.
May 22, 2025 11:00 AM GMT
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today annou